David A. Bristol
Directeur/Membre du Conseil chez HCF Enterprises, Inc.
Profil
David A.
Bristol is currently a Director at HCF Enterprises, Inc. and Sentinel Private Equity XVI Fund.
He was previously a Director at Nanospectra Biosciences, Inc. and a Geophysicist at Exxon Co. USA from 1988 to 1991.
Bristol received his undergraduate degree from Brown University and his graduate degree from The University of Texas at Austin.
Postes actifs de David A. Bristol
| Sociétés | Poste | Début |
|---|---|---|
| HCF Enterprises, Inc. | Directeur/Membre du Conseil | - |
| Sentinel Private Equity XVI Fund | Directeur/Membre du Conseil | - |
Anciens postes connus de David A. Bristol
| Sociétés | Poste | Fin |
|---|---|---|
| Exxon Co. USA | Corporate Officer/Principal | 02/01/1991 |
Nanospectra Biosciences, Inc.
 Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Directeur/Membre du Conseil | - |
Formation de David A. Bristol
| Brown University | Undergraduate Degree |
| The University of Texas at Austin | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Health Technology |
| Exxon Co. USA | |
| Sentinel Private Equity XVI Fund | |
| HCF Enterprises, Inc. |
